Suppr超能文献

SGLT2抑制剂使用与高甘油三酯血症背景下的正常血糖性糖尿病酮症酸中毒:一例报告及文献综述

Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature.

作者信息

Gajjar Kushani, Luthra Pooja

机构信息

Internal Medicine, University of Connecticut Health Center, Farmington, USA.

出版信息

Cureus. 2019 Apr 4;11(4):e4384. doi: 10.7759/cureus.4384.

Abstract

We describe the case report of a patient with euglycemic diabetic ketoacidosis (euDKA), in the setting of sodium-glucose cotransporter-2 (SGLT2) inhibitor use, complicated by hypertriglyceridemia (HTG). A 28-year-old female with a history of gestational diabetes mellitus and subsequent type 2 diabetes mellitus (T2DM) on dapagliflozin and metformin presented with a one-week history of polyuria, poor appetite, and vomiting. On admission, serum glucose was 111 mg/dl, bicarbonate 18 mmol/l, anion gap 20, triglycerides 508 mg/dL, and venous pH 7.27. Serum ketone levels could not be assessed, as blood samples kept hemolyzing due to significant lipemia. The patient was initially admitted for starvation ketosis. However, serum chemistry obtained six hours after presentation revealed no change in the anion gap and a rise in triglycerides. She was treated with an insulin drip for euDKA and HTG with the resolution of the clinical picture. We performed a literature review of this topic and discuss the pathophysiology, diagnosis, management, and prevention of SGLT2-inhibitor-induced euDKA.

摘要

我们报告了一例在使用钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂的情况下发生正常血糖性糖尿病酮症酸中毒(euDKA)并伴有高甘油三酯血症(HTG)的病例。一名28岁女性,有妊娠期糖尿病病史,后续诊断为2型糖尿病(T2DM),正在使用达格列净和二甲双胍治疗,出现多尿、食欲减退和呕吐一周。入院时,血清葡萄糖为111mg/dl,碳酸氢盐为18mmol/l,阴离子间隙为20,甘油三酯为508mg/dL,静脉血pH值为7.27。由于严重脂血导致血样持续溶血,无法评估血清酮水平。患者最初因饥饿性酮症入院。然而,就诊六小时后检测的血清化学指标显示阴离子间隙无变化,甘油三酯升高。她接受了胰岛素静脉滴注治疗,euDKA和HTG得到缓解,临床症状消失。我们对该主题进行了文献综述,并讨论了SGLT2抑制剂诱导的euDKA的病理生理学、诊断、管理和预防。

相似文献

3
Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
AACE Clin Case Rep. 2020 Dec 28;7(1):17-19. doi: 10.1016/j.aace.2020.11.009. eCollection 2021 Jan-Feb.
5
Fall, Fracture, and Two Episodes of Euglycemic Diabetic Ketoacidosis.
Cureus. 2022 Jun 9;14(6):e25788. doi: 10.7759/cureus.25788. eCollection 2022 Jun.
6
Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip.
Cureus. 2022 Jan 31;14(1):e21768. doi: 10.7759/cureus.21768. eCollection 2022 Jan.
8
Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
J Emerg Med. 2017 Feb;52(2):223-226. doi: 10.1016/j.jemermed.2016.07.082. Epub 2016 Oct 4.
10
Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.
J Investig Med High Impact Case Rep. 2017 May 24;5(2):2324709617710040. doi: 10.1177/2324709617710040. eCollection 2017 Apr-Jun.

引用本文的文献

1
Unmasking Euglycemic Diabetic Ketoacidosis: The Interplay of Pregnancy, Sepsis, and Glucagon-Like Peptide 1 Analog.
Cureus. 2025 Jan 29;17(1):e78193. doi: 10.7759/cureus.78193. eCollection 2025 Jan.
2
Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis Masked by Urinary Tract Infection.
Cureus. 2024 Aug 7;16(8):e66408. doi: 10.7759/cureus.66408. eCollection 2024 Aug.
3
Sodium-glucose transport protein 2 inhibitor use in the management of insulin dysregulation in ponies and horses.
J Vet Pharmacol Ther. 2025 Jan;48 Suppl 1(Suppl 1):31-40. doi: 10.1111/jvp.13470. Epub 2024 Jul 10.
6
Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus.
Cureus. 2023 Jan 17;15(1):e33892. doi: 10.7759/cureus.33892. eCollection 2023 Jan.
7
SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
Cureus. 2022 Jun 23;14(6):e26267. doi: 10.7759/cureus.26267. eCollection 2022 Jun.
8
Trimetazidine Blocks Lipid Oxidation-Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis?
J Diabetes Sci Technol. 2022 Sep;16(5):1063-1068. doi: 10.1177/19322968221100196. Epub 2022 Jun 2.

本文引用的文献

2
Risks Associated with SGLT2 Inhibitors: An Overview.
Curr Drug Saf. 2018;13(2):84-91. doi: 10.2174/1574886313666180226103408.
4
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
N Engl J Med. 2017 Jun 8;376(23):2300-2302. doi: 10.1056/NEJMc1701990.
5
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
Diabetes Res Clin Pract. 2017 Aug;130:53-60. doi: 10.1016/j.diabres.2017.04.017. Epub 2017 May 18.
6
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
Diabetologia. 2017 Aug;60(8):1385-1389. doi: 10.1007/s00125-017-4301-8. Epub 2017 May 12.
7
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
Diabetes Metab Res Rev. 2017 Jul;33(5). doi: 10.1002/dmrr.2886. Epub 2017 Feb 23.
8
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Clin Ther. 2016 Dec;38(12):2654-2664.e1. doi: 10.1016/j.clinthera.2016.11.002.
9
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Pharmacotherapy. 2017 Feb;37(2):187-194. doi: 10.1002/phar.1881. Epub 2017 Jan 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验